Stoneridge Investment Partners LLC Takes Position in ANI Pharmaceuticals Inc (ANIP)

Stoneridge Investment Partners LLC Takes Position in ANI Pharmaceuticals Inc (ANIP)

Stoneridge Investment Partners LLC acquired a new position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 9,730 shares of the specialty pharmaceutical company’s stock, valued at approximately $482,000. Stoneridge Investment Partners LLC owned approximately 0.08% of ANI Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ANIP. BlackRock Fund Advisors raised its position in ANI Pharmaceuticals by 8.7% in the third quarter. BlackRock Fund Advisors now owns 718,640 shares of the specialty pharmaceutical company’s stock worth $47,682,000 after buying an additional 57,809 shares in the last quarter. Renaissance Technologies LLC raised its position in ANI Pharmaceuticals by 21.9% in the fourth quarter. Renaissance Technologies LLC now owns 232,700 shares of the specialty pharmaceutical company’s stock worth $14,106,000 after buying an additional 41,800 shares in the last quarter. Dimensional Fund Advisors LP raised its position in ANI Pharmaceuticals by 90.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 91,514 shares of the specialty pharmaceutical company’s stock worth $5,548,000 after buying an additional 43,534 shares in the last quarter. Guggenheim Capital LLC raised its position in ANI Pharmaceuticals by 163.9% in the fourth quarter. Guggenheim Capital LLC now owns 51,415 shares of the specialty pharmaceutical company’s stock worth $3,117,000 after buying an additional 31,935 shares in the last quarter. Finally, Dana Investment Advisors Inc. bought a new position in ANI Pharmaceuticals during the third quarter worth approximately $1,942,000. 51.56% of the stock is currently owned by institutional investors.

Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) traded down 4.13% during trading on Friday, reaching $48.02. The company’s stock had a trading volume of 300,462 shares. The stock’s 50 day moving average price is $49.77 and its 200-day moving average price is $56.64. ANI Pharmaceuticals Inc has a 52-week low of $43.42 and a 52-week high of $70.92. The stock has a market cap of $556.50 million, a price-to-earnings ratio of 141.24 and a beta of 3.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, May 4th. The specialty pharmaceutical company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.04. ANI Pharmaceuticals had a return on equity of 21.84% and a net margin of 7.28%. The business earned $36.60 million during the quarter, compared to analysts’ expectations of $39.63 million. During the same quarter last year, the business posted $0.76 EPS. The business’s revenue was up 77.7% on a year-over-year basis. Equities analysts anticipate that ANI Pharmaceuticals Inc will post $3.87 EPS for the current year.

A number of equities analysts recently commented on ANIP shares. Roth Capital set a $56.00 price objective on ANI Pharmaceuticals and gave the stock a “hold” rating in a research note on Saturday, March 4th. Guggenheim reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, March 3rd. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, TheStreet lowered ANI Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Monday, April 3rd. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $67.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Related posts

Leave a Comment